Lyell Immunopharma, Inc. announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A veteran biotech leader with more than a decade of experience heading translational cell and gene therapy programs, Dr. Lee will set and oversee the company's research strategy and advance its research pipeline. Before joining Lyell, Dr. Lee served as Chief Scientific Officer at Senti Bio.

Prior to that he held scientific and leadership positions of increasing responsibility at Sangamo Therapeutics. As Sangamo's Vice President of Cell Therapy, Dr. Lee led the company's T-cell engineering programs. Lyell also announced toay that Dr. Nick Restifo, Executive Vice President, Research, will transition to a role as scientific advisor effective February 15, 2022. Dr. Restifo will continue to provide scientific insight on Lyell's programs and research pipeline, with a particular focus on its Epi-R™ and Rejuvenation platforms.